The major players in the erectile dysfunction (ED) drugs market are Eli Lilly and Co., Pfizer, Bayer AG, Dong-A Pharmaceutical Co. Ltd., Vivus, Meda Pharmaceuticals, Apricus Biosciences, Cristália, SK Chemicals Co and Teva Pharmaceutical Industries Ltd. .
New York, March 16, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the publication of the “Drugs For Erectile Dysfunction Global Market Report 2022” – https://www.reportlinker.com/p06245019/?utm_source=GNW
The global erectile dysfunction drugs market is expected to grow from $3.09 billion in 2021 to $3.18 billion in 2022 at a compound annual growth rate (CAGR) of 2.8%. The growth is mainly due to companies reorganizing their operations and recovering from the impact of COVID-19, which had previously led to restrictive containment measures involving social distancing, remote working and the closure of business activities that resulted in operational challenges. The market is expected to reach $3.36 billion in 2026 at a CAGR of 1.3%.
The erectile dysfunction (ED) drugs market consists of the sale of erectile dysfunction (ED) drugs and related services. Erectile dysfunction is the inability to achieve or maintain a penile erection in men.
The different types of erectile dysfunction (ED) drugs are sildenafil citrate, mirodenafil, vardenafil. Sildenafil is a drug used to treat erectile dysfunction and pulmonary arterial hypertension.
It is offered under the trade names Viagra and others. It is not known if it is effective in treating female genital dysfunction.
The different routes of administration include oral, topical injections and are used by hospital pharmacies, retail pharmacies and online pharmacies.
North America is the largest region for erectile dysfunction (ED) drugs market in 2021. Middle East is expected to be the fastest growing region during the forecast period.
Regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The drastic increase in the number of chronic diseases is driving the market for erectile dysfunction drugs. Erectile dysfunction is mainly caused by chronic diseases resulting from a sedentary lifestyle such as cardiovascular disease, diabetes, obesity and high blood pressure.
According to WHO, the prevalence of chronic diseases is expected to increase by 57% by the end of the year 2020. The prevalence of chronic diseases increases the risks of erectile dysfunction in men, thus driving the erectile dysfunction drugs market erectile.
Patients with erectile dysfunction do not seek treatment due to factors such as lack of education, lack of awareness, strong religious beliefs, social taboo, and low socioeconomic status. These factors are responsible for the rejection or avoidance of patients with erectile dysfunction. processing.
For example, according to a survey conducted by Opinium Research in February 2020, only 27% of a total of 2,006 men surveyed knew that erectile dysfunction could be linked to high blood pressure or high cholesterol, while only 22% of men surveyed knew that erection dysfunction is often associated with diabetes. These factors are restraining the growth of the erectile dysfunction drugs market.
New drug delivery techniques such as the use of lozenges and creams are being implemented by many companies in the erectile dysfunction drug market. Lozenges and creams will have more efficacy and performance in erectile dysfunction and they are also more effective and safer to use.
These advantages of drug delivery techniques will increase the scope of erectile dysfunction drugs market. For example, in 2019, Futura Medical, a UK-based healthcare company, announced the development of a gel product, named MED2005, as a therapeutic treatment for erectile dysfunction.
Drugs are licensed by regulatory bodies on the basis of quality, safety, and efficacy to ensure that drugs are of standard quality and provide positive benefits. Companies are required to submit standard quality documentation before applying for approval.
Drug safety and efficacy must be demonstrated through clinical trials for all new drugs by companies. The competent authorities will assess this data before authorizing the medicinal products.
In Europe, the European Medicines Agency (EMA) assesses medicines for centrally authorized products.
The countries covered in the Erectile Dysfunction (ED) Drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the United Kingdom and the United States.
Read the full report: https://www.reportlinker.com/p06245019/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001